Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses

Cell Research

Volumn 23, Issue 12, 2013, Pages 1347-1355

  Wu, Yan ^a,b   Bi, Yuhai ^a   Vavricka, Christopher J ^a,c   Sun, Xiaoman ^a,b   Zhang, Yanfang ^d   Gao, Feng ^c,e   Zhao, Min ^a   Xiao, Haixia ^d   Qin, Chengfeng ^f   He, Jianhua ^g   Liu, Wenjun ^a   Yan, Jinghua ^a   Qi, Jianxun ^a   Gao, George F ^a,b,c,d,h  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d Tianjin Airport Economic Area   (China)

^e SICHUAN UNIVERSITY   (China)

^f BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^g SHANGHAI INSTITUTE OF APPLIED PHYSICS   (China)

^h CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Drug Resistance; H7N9; Neuraminidase; Sialidase Activity; Structural Basis; Virus Fitness

Indexed keywords

AVES; ORTHOMYXOVIRIDAE;

ANTIVIRUS AGENT; OSELTAMIVIR; SIALIDASE;

AMINO ACID SEQUENCE; ANIMAL; ANTIVIRAL RESISTANCE; ARTICLE; BINDING SITE; BIRD; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; INFLUENZA VIRUS A H7N9; KINETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN BINDING; VIROLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; BINDING SITES; BIRDS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; KINETICS; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PROTEIN BINDING;

EID: 84889102673     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2013.144     Document Type: Article

References (35)

1. Xu R, Zhu X, McBride R, et al. Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. J Virol 2012; 86:9221-9232.
2. Moscona A. Medical management of influenza infection. Annu Rev Med 2008; 59:397-413.
3. Ison MG. Clinical use of approved influenza antivirals: Therapy and prophylaxis. Influenza Other Respi Viruses 2012; 7:7-13.
4. Vavricka CJ, Li Q, Wu Y, et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog 2011; 7:e1002249.
5. Li Q, Sun X, Li Z, et al. Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. Proc Natl Acad Sci USA 2012; 109:18897-18902.
6. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443:45-49.
7. Liu D, Shi W, Shi Y, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: Phylogenetic, structural, and coalescent analyses. Lancet 2013; 381:1926-1932.
8. Sorrell EM, Song H, Pena L, Perez DR. A 27-amino-acid deletion in the neuraminidase stalk supports replication of an avian H2N2 influenza A virus in the respiratory tract of chickens. J Virol 2010; 84:11831-11840.
9. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-1897.
10. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992; 14:327-332.
11. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-2279.
12. Varghese JN, Smith PW, Sollis SL, et al. Drug design against a shifting target: A structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998; 6:735-746.
13. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004; 364:759-765.
14. Tai CY, Escarpe PA, Sidwell RW, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42:3234-3241.
15. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71:3385-3390.
16. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005; 49:4075-4084.
17. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002; 54:79-88.
18. Vavricka CJ, Liu Y, Kiyota H, et al. Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. Nat Commun 2013; 4:1491.
19. Li Q, Qi J, Zhang W, et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 2010; 17:1266-1268.
20. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2enderived inhibitors. J Virol 1998; 72:2456-2462.
21. Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: Public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12:240-248.
22. de Wit E, Spronken MI, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments. Virus Res 2004; 103:155-161.
23. Sun Y, Qin K, Wang J, et al. High genetic compatibility and increased pathogenicity of reassortants derived from avian H9N2 and pandemic H1N1/2009 influenza viruses. Proc Natl Acad Sci USA 2011; 108:4164-4169.
24. Zhang Y, Yin Y, Bi Y, et al. Molecular and antigenic characterization of H9N2 avian influenza virus isolates from chicken flocks between 1998 and 2007 in China. Vet Microbiol 2012; 156:285-293.
25. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hygiene 1938; 27:493-497.
26. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 2008; 82:10493-10501.
27. Wu Y, Qin G, Gao F, et al. Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Sci Rep 2013; 3:1551.
28. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997; 276:307-326.
29. Read RJ. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr 2001; 57:1373-1382.
30. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994; 50:760-763.
31. Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126-2132.
32. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53:240-255.
33. Adams PD, Grosse-Kunstleve RW, Hung LW, et al. PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 2002; 58:1948-1954.
34. Laskowski R MM, Moss D, Thornton J. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26:283-291.
35. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N- acetylneuraminate) substrate. Anal Biochem 1979; 94:287-296.